Our findings suggest that Lyc.HCL may inhibit ESCC cell proliferation by simultaneously targeting both the JAK2/STAT3 and ERK pathways, underscoring its potential as a multi-target therapeutic agent for ESCC. Here, STAT3 is linked to esophageal squamous cell carcinoma.